Autres langues Allogene Therapeutics, Inc.

Actions

ALLO

US0197701065

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 19/04/2024			Varia. 5j.	Varia. 1 janv.
3,47 ^USD	+0,29 %		-8,68 %	+8,10 %

15/03	Allogene Therapeutics dépose une déclaration d'enregistrement mixte de 500 millions de dollars	MT
14/03	Transcript : Allogene Therapeutics, Inc., Q4 2023 Earnings Call, Mar 14, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Allogene Therapeutics Announces Q2 Investor Conference Participation	09/04
Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index	18/03
Allogene Therapeutics Files $500 Million Mixed Shelf	15/03
Allogene Therapeutics Q4 Loss Narrows, Revenue Drops	14/03
Allogene Therapeutics: Q4 Earnings Snapshot	14/03
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update	14/03
Allogene Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	14/03
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease	12/03
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update	05/03
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference	28/02
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference	28/02
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia	19/02
Allogene Therapeutics to Restate Financial Statements Due to Accounting Adjustments	16/02
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia	16/02
Allogene Therapeutics, Inc. Announces Restate Financial Statements for the Years Ended December 31, 2020, 2021 and 2022 and Interim Quarters During 2022 and 2023	16/02
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences	16/01
North American Morning Briefing : Boeing Drags -2-	08/01
Aktien New York: Anleger nach US-Wirtschaftsdaten hin- und hergerissen	05/01
Aktien New York: Trübe Stimmung im Servicesektor wirkt positiv	05/01
Allogene Therapeutics to Lay off 22% of Workforce; Partners With Foresight to Develop in Vitro Diagnostic	05/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Allogene Therapeutics, Inc.

Actions

ALLO

US0197701065

Autres langues

Filtres